• In recent days, PROCEPT BioRobotics has attracted heightened attention as multiple Wall Street firms updated their views on the company, with new coverage, ratings changes, and fresh commentary on its robotic treatments for benign prostatic hyperplasia.
• The mix of supportive and more cautious analyst opinions reinforces how central PROCEPT’s Aquablation technology and utilization trends are to investor expectations around its future role in urologic care.
• We’ll now examine how this new wave of analyst attention, especially the differing views on Aquablation utilization, could reshape PROCEPT BioRobotics’ investment narrative.

Outshine the giants: these 28 early-stage AI stocks could fund your retirement.

PROCEPT BioRobotics Investment Narrative Recap

To own PROCEPT BioRobotics, you need to believe Aquablation can keep gaining share in benign prostatic hyperplasia while the company works through ongoing losses and heavy R&D spend. The latest mix of analyst upgrades, downgrades, and price target changes mainly reframes expectations around near term utilization trends, without materially changing the key catalyst of broader Aquablation adoption or the central risk that procedure growth could slow from here.

UBS’s new coverage with a US$62 price target, grounded in consultations pointing to utilization growth through 2026 and 2027, directly ties into this catalyst by emphasizing how hospital and surgeon adoption patterns may shape PROCEPT’s trajectory. Set against Bank of America’s downgrade on concerns about slowing utilization growth, this split in views underlines how sensitive the story is to Aquablation procedure volumes and whether they can justify continued investment and operating losses.

Yet behind the optimism on Aquablation adoption, investors should also be aware of the risk that utilization growth could slow and...

PROCEPT BioRobotics' narrative projects $563.8 million revenue and $70.4 million earnings by 2028. This requires 27.0% yearly revenue growth and a $154.5 million earnings increase from -$84.1 million today.

Uncover how PROCEPT BioRobotics' forecasts yield a $50.73 fair value, a 47% upside to its current price.

Exploring Other Perspectives

Eight members of the Simply Wall St Community currently see fair value for PROCEPT BioRobotics between US$27.49 and US$85, underscoring how far opinions can stretch. You can weigh these views against the central question of whether Aquablation utilization will grow fast enough to offset ongoing losses and justify today’s price, and then explore several alternative viewpoints before deciding how this fits into your own expectations.

Explore 8 other fair value estimates on PROCEPT BioRobotics - why the stock might be worth 20% less than the current price!

Build Your Own PROCEPT BioRobotics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your PROCEPT BioRobotics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free PROCEPT BioRobotics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate PROCEPT BioRobotics' overall financial health at a glance.

No Opportunity In PROCEPT BioRobotics?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• We've found 11 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• These 16 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• Rare earth metals are the new gold rush. Find out which 39 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.